Cyheptamide. A pharmacological evaluation.
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000435:Alcoholic Intoxication; D000818:Animals; D000927:Anticonvulsants / Q000494:pharmacology* / Q000633:toxicity; D001794:Blood Pressure / Q000187:drug effects; D001831:Body Temperature / Q000187:drug effects; D001980:Bronchi / Q000187:drug effects; D002389:Catatonia / Q000139:chemically induced; D003986:Dibenzocycloheptenes / Q000494:pharmacology* / Q000633:toxicity; D004336:Drug Antagonism; D004357:Drug Synergism; D004597:Electroshock; D005769:Gastrointestinal Motility / Q000187:drug effects; D006321:Heart / Q000187:drug effects; D006634:Histamine H1 Antagonists / Q000494:pharmacology; D006801:Humans; D007717:Knee; D008297:Male; D008717:Methionine Sulfoximine / Q000037:antagonists & inhibitors; D051379:Mice; D009043:Motor Activity / Q000187:drug effects; D009420:Nervous System / Q000187:drug effects; D009469:Neuromuscular Junction / Q000187:drug effects; D010433:Pentylenetetrazole / Q000037:antagonists & inhibitors; D011930:Reaction Time / Q000187:drug effects; D012018:Reflex / Q000187:drug effects; D012154:Reticular Formation / Q000502:physiology; D013035:Spasm / Q000188:drug therapy; D013331:Strychnine / Q000037:antagonists & inhibitors; D014202:Tremor / Q000188:drug therapy
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D000927:Anticonvulsants; D003986:Dibenzocycloheptenes; D006634:Histamine H1 Antagonists; D008717:Methionine Sulfoximine; D013331:Strychnine; D010433:Pentylenetetrazole